EP Patent

EP4601631A1 — Combination for use in treating cancers

Assigned to Mapkure LLC · Expires 2025-08-20 · 1y expired

What this patent protects

The present disclosure relates to methods of treating cancers comprising co-administration of mirdametinib (Compound A) or a pharmaceutically acceptable salt thereof, and 1-((1S,1aS,6bS)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofu…

USPTO Abstract

The present disclosure relates to methods of treating cancers comprising co-administration of mirdametinib (Compound A) or a pharmaceutically acceptable salt thereof, and 1-((1S,1aS,6bS)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl)-3-(2,4,5-trifluorophenyl) urea (Compound B) or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP4601631A1
Jurisdiction
EP
Classification
—
Expires
2025-08-20
Drug substance claim
No
Drug product claim
No
Assignee
Mapkure LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.